SSAT066 Renal Integrase Study

• Research type

  Research Study

• Full title

  A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal tubular function and renal transporters in HIV-1 antiretroviral naïve patients

• IRAS ID

  169686

• Contact name

  Graeme Moyle

• Contact email

  gm@moyleg.demon.co.uk

• Sponsor organisation

  St Stephen's AIDS Trust

• Eudract number

  2014-004578-40

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  The purpose of this study is to observe the safety of Truvada® (TDF/FTC) in relation to its impact on kidney function combined with different Integrase Inhibitors (Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir), when given to patients who are commencing treatment for HIV infection for the first time.
  All three combinations (Raltegravir + Truvada®, Dolutegravir + Truvada® and Stribild®, a single pill which contains Elvitegravir/Cobicistat/Truvada®) are currently recommended by the national guide-lines and used in standard clinical practice.

  The study will monitor kidney function, and compare the safety and effectiveness of Truvada® when taken with Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir, over the first 48 weeks of treatment in HIV-1 antiretrovirals naïve patients.
  The safety and how well these drug combinations are tolerated will be determined based on physical examinations, laboratory tests, and questions about any problems the participant might experience during the study. As part of this trial, levels of HIV-1 in the blood and urinary markers of kidney function and inflammatory markers will be measured at various times during the study.
  The total duration of participant involvement in the trial will be up to 48 weeks, with up to 45 days between the screening and baseline visits. Participants will need to visit the clinic 6 times within the 48 weeks.
  Once participants have been confirmed to be eligible to participate in the study, participants will attend for a baseline visit (day 1) where they will be randomly assigned to receive one of the three treatments listed below:
  • Treatment Arm 1: Stribild® (EVG/COBI/FTC/TDF) 1 tablet once a day
  • Treatment Arm 2: Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® 1 tablet once a day
  • Treatment Arm 3: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® 1 tablet once a day

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  15/LO/0031

• Date of REC Opinion

  15 Jan 2015

• REC opinion

  Favourable Opinion